Abstract
Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Keywords: Vascular endothelial growth factor, angiogenesis, endothelium, homeostasis, cardiotoxicity, hypertension, nitric oxide, clinical trials, vascular endothelial growth factor receptor, renin angiotensin system, cytokines, interleukin
Current Vascular Pharmacology
Title: The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Volume: 9 Issue: 3
Author(s): Shivshankar Thanigaimani, Ganessan Kichenadasse and Arduino A. Mangoni
Affiliation:
Keywords: Vascular endothelial growth factor, angiogenesis, endothelium, homeostasis, cardiotoxicity, hypertension, nitric oxide, clinical trials, vascular endothelial growth factor receptor, renin angiotensin system, cytokines, interleukin
Abstract: Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Export Options
About this article
Cite this article as:
Thanigaimani Shivshankar, Kichenadasse Ganessan and A. Mangoni Arduino, The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495503
DOI https://dx.doi.org/10.2174/157016111795495503 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Current Drug Safety Prevalence of Analgesic Use and Pain in People with and without Dementia or Cognitive Impairment in Aged Care Facilities: A Systematic Review and Meta-Analysis
Current Clinical Pharmacology Antiangiogenic Therapy for High-Grade Gliomas
CNS & Neurological Disorders - Drug Targets The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Role of 1,4-Benzothiazine Derivatives in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Editorial Statins: [Hot Topic: Statins: Effects Beyond Cholesterol Lowering (Guest Editor: Garry X. Shen)]
Current Drug Targets - Cardiovascular & Hematological Disorders Is Erectile Dysfunction an Example of Abnormal Endothelial Function?
Current Vascular Pharmacology Editorial [Hot Topic: Cardiovascular Diagnostic Testing: Use and Limits of Biochemical Markers (Executive Editors: Aurelio Leone and Stefano Taddei)]
Current Pharmaceutical Design Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Factors Associated with Primary Hypertension in Pediatric Patients: An Up-to-Date
Current Pediatric Reviews Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Lipid Management and Peripheral Arterial Disease
Current Drug Targets Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists
Current Computer-Aided Drug Design Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews Application of MALDI-TOF Mass Spectrometry in Screening and Diagnostic Research
Current Pharmaceutical Design